Home › Trial NCT05374226
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
- Trial IDNCT05374226
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorSuzhou Kebo Ruijun Biotechnology Co., Ltd
- Enrollment172
- Start date2022-03-31
- ConditionsAdvanced Solid Tumors or Lymphomas
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.